FAQ

ARC 1779

Known as: ARC-1779, ARC1779 
 

Topic mentions per year

Topic mentions per year

2007-2011
02420072011

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2012
2012
Initial experience from a double-blind, placebo-controlled, clinical outcome study of ARC1779 in patients with thrombotic thrombocytopenic purpura.
 
Is this relevant?
2011
2011
Inhibition of von Willebrand factor by ARC1779 in patients with acute thrombotic thrombocytopenic purpura.
Thrombotic thrombocytopenic purpura (TTP) can cause severe organ damage due to enhanced platelet aggregation by ultra-large von… (More)
Is this relevant?
2011
2011
A dose ranging phase I/II trial of the von Willebrand factor inhibiting aptamer ARC1779 in patients with congenital thrombotic thrombocytopenic purpura.
Congenital thrombotic thrombocytopenic purpura (TTP) is a very rare but potentially life-threatening disorder. This phase I/II… (More)
Is this relevant?
2010
2010
A randomised pilot trial of the anti-von Willebrand factor aptamer ARC1779 in patients with type 2b von Willebrand disease.
Desmopressin aggravates thrombocytopenia in type 2B von Willebrand disease (VWF type 2B) by release of large and hyper-adhesive… (More)
Is this relevant?
2010
2010
The aptamer ARC1779 blocks von Willebrand factor-dependent platelet function in patients with thrombotic thrombocytopenic purpura ex vivo.
BACKGROUND In thrombotic thrombocytopenic purpura (TTP), ultralarge von Willebrand factor (VWF) multimers bind platelet (PLT… (More)
Is this relevant?
2009
2009
Inhibition of von Willebrand factor-mediated platelet activation and thrombosis by the anti-von Willebrand factor A1-domain aptamer ARC1779.
BACKGROUND von Willebrand factor (VWF) has a role in both hemostasis and thrombosis. Platelets adhere to damaged arteries by… (More)
Is this relevant?
2009
2009
ARC-1779, a PEGylated aptamer antagonist of von Willebrand factor for potential use as an anticoagulant or antithrombotic agent.
Archemix Corp's ARC-1779 is an optimized, second-generation, PEGylated aptamer that exerts a novel antithrombotic action through… (More)
Is this relevant?
2009
2009
Anti-von Willebrand factor aptamer ARC1779 for refractory thrombotic thrombocytopenic purpura.
BACKGROUND Plasma exchange is the main therapy for thrombotic thrombocytopenic purpura (TTP). No treatments other than plasma… (More)
Is this relevant?
2009
2009
The aptamer ARC1779 is a potent and specific inhibitor of von Willebrand Factor mediated ex vivo platelet function in acute myocardial infarction.
ARC1779 is an aptamer, which blocks binding of the von Willebrand Factor (VWF) A1 domain to platelet GPIb receptors. VWF is… (More)
  • table I
  • table II
  • figure 1
  • figure 2
  • table III
Is this relevant?
Highly Cited
2007
Highly Cited
2007
First-in-human evaluation of anti von Willebrand factor therapeutic aptamer ARC1779 in healthy volunteers.
BACKGROUND ARC1779 is a therapeutic aptamer antagonist of the A1 domain of von Willebrand Factor (vWF), the ligand for receptor… (More)
  • figure 1
  • figure 2
  • table 1
  • table 2
  • figure 3
Is this relevant?